Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F

Daix (France), New York City (New York, United States), April 15, 2025– Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that it had filed its 2024 Universal Registration Document for the year ended December 31,...

DAIX, 15/04/2025 (informazione.news - comunicati stampa - salute e benessere)

– Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that it had filed its 2024 Universal Registration Document for the year ended December 31, 2024, including the management report and the annual financial report, with the French “Autorité des Marchés Financiers” (“AMF”) and its 2024 Annual Report on Form 20-F for the year ended December 31, 2024 with the U.S. Securities and Exchange Commission (“SEC”).

These documents can be accessed on the “Investors” section of the Company's corporate website (www.inventivapharma.com). In addition, the 2024 Universal Registration Document is available on the website of the AMF (www.amf-france.org) and the 2024 Annual Report on Form 20-F is also available on the website of
the SEC (www.sec.gov).

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.

The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN:
FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA).
http://www.inventivapharma.com

Attachment